INT94132

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.13
First Reported 2001
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 7
Total Number 10
Disease Relevance 2.62
Pain Relevance 4.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (ACOT1) lipid metabolic process (ACOT1) cytoplasm (ACOT1)
Anatomy Link Frequency
neuronal 1
FBT 1
ACOT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
sSRI 21 100.00 Very High Very High Very High
fluoxetine 18 100.00 Very High Very High Very High
Nicotine 44 99.98 Very High Very High Very High
tricyclic antidepressant 6 98.44 Very High Very High Very High
positron emission tomography 10 98.06 Very High Very High Very High
antagonist 6 96.88 Very High Very High Very High
Potency 5 96.48 Very High Very High Very High
agonist 37 93.32 High High
Analgesic 3 90.72 High High
Morphine 9 89.04 High High
Disease Link Frequency Relevance Heat
Disease 206 99.60 Very High Very High Very High
Cognitive Disorder 63 96.76 Very High Very High Very High
Hallucination 9 89.20 High High
Depression 23 86.20 High High
Immunization 21 75.88 Quite High
Neurodegenerative Disease 6 68.84 Quite High
Alzheimer's Dementia 21 64.24 Quite High
Meningoencephalitis 3 53.76 Quite High
Dementia 30 53.28 Quite High
Sleep Disorders 3 45.56 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We compared the interaction of fluoxetine and paroxetine, two selective serotonin reuptake inhibitors (SSRIs), with the human (h) alpha4beta2, alpha3beta4, and alpha7 nicotinic acetylcholine receptors (AChRs) in different conformational states, using Ca(2+) influx, radioligand binding, and molecular docking approaches.
AChRs Binding (interaction) of associated with ssri and fluoxetine
1) Confidence 0.13 Published 2010 Journal Biochemistry Section Abstract Doc Link 20527991 Disease Relevance 0 Pain Relevance 0.53
On two of the occasions PET scans were performed using [(18)F] (+)-4-fluorobenzyltrozamicol ([(18)F]FBT), which selectively binds to the vesicular acetylcholine (ACh) transporter in the presynaptic cholinergic terminals.
ACh Binding (binds) of in FBT associated with positron emission tomography
2) Confidence 0.10 Published 2001 Journal Pain Section Abstract Doc Link 11240086 Disease Relevance 0 Pain Relevance 1.39
In conclusion, SSRIs inhibit the most important neuronal AChRs with potencies and affinities that are clinically relevant by binding to a luminal site that is shared with tricyclic antidepressants.
AChRs Binding (binding) of in neuronal associated with tricyclic antidepressant and ssri
3) Confidence 0.10 Published 2010 Journal Biochemistry Section Abstract Doc Link 20527991 Disease Relevance 0 Pain Relevance 0.66
[corrected] (2) SSRIs bind to the [(3)H]imipramine locus with a [corrected] higher affinity when the AChRs are in the desensitized states compared to the resting states. (3) The different receptor specificity for fluoxetine determined by their inhibitory potencies or binding affinities suggests different modes of interaction when the AChR is in the closed or activated state. (4) Neutral and protonated fluoxetine interacts with a binding domain located in the middle of the AChR ion channel.
AChRs Spec (determined) Binding (bind) of associated with ssri and fluoxetine
4) Confidence 0.10 Published 2010 Journal Biochemistry Section Abstract Doc Link 20527991 Disease Relevance 0 Pain Relevance 0.73
Tricyclic antidepressants have a similar efficacy but are used less often because most have prominent anticholinergic side effects, which have the potential to counteract the AChEI given as a treatment [76, 79].
AChEI Binding (counteract) of associated with tricyclic antidepressant
5) Confidence 0.07 Published 2007 Journal Current Genomics Section Body Doc Link PMC2647161 Disease Relevance 0.83 Pain Relevance 0.33
Memantine can be combined safely with AChEIs for an additional symptomatic benefit.
AChEIs Binding (combined) of
6) Confidence 0.06 Published 2007 Journal Current Genomics Section Abstract Doc Link PMC2647161 Disease Relevance 0.72 Pain Relevance 0.05
AChEIs can be combined safely with memantine for an additional symptomatic benefit.
AChEIs Binding (combined) of
7) Confidence 0.06 Published 2007 Journal Current Genomics Section Body Doc Link PMC2647161 Disease Relevance 1.00 Pain Relevance 0
Our results are verified by site-directed mutagenesis and electrophysiological experiments, and suggest that APL and ACh bind to different sites on nicotinic receptors and that allosteric potentiation may arise from a direct interplay between both these sites.
ACh Binding (bind) of
8) Confidence 0.03 Published 2009 Journal ChemMedChem Section Abstract Doc Link 19739198 Disease Relevance 0.07 Pain Relevance 0.12
Again, the predicted energies of acetylcholine and nicotine binding to AChBP are close to those for binding to nAChRs (Table 1 – top).
AChBP Binding (binding) of associated with nicotine
9) Confidence 0.03 Published 2002 Journal BMC Struct Biol Section Body Doc Link PMC65631 Disease Relevance 0 Pain Relevance 0.12
Low-energy conformations were found only in the absence of water molecule, and the calculated binding energies (Table 1 – bottom) suggest that HEPES is a poor ligand for nAChRs, and AChBP, and was observed in the crystal structure because of its high concentration (100 mM) in the crystallization condition [6].
AChBP Binding (ligand) of
10) Confidence 0.02 Published 2002 Journal BMC Struct Biol Section Body Doc Link PMC65631 Disease Relevance 0 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox